BioSpace News Archive

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the first quarter of fiscal 2021 ended December 31, 2020.

Fourth Quarter 2020 Year-Over-Year: - Product Sales increased 26% to $7.3 billion, primarily due to Veklury ® (remdesivir) - - Diluted EPS of $1.23; Non-GAAP Diluted EPS of $2.19 - Full Year 2020 Year-Over-Year: - Product Sales increased 10% to $24.4 billion, primarily due to Veklury - - Diluted EPS of $0.10; Non-GAAP Diluted EPS of $7.09 -

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance exchange, announced today that the company plans to release fourth quarter and fiscal year 2020 financial results on February 18, 2021.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that its Board of Directors has approved several promotions within the senior management team, including Gregory Carven, Ph.D. to Chief Scientific Officer, Junlin Ho, J.D. to General Counsel and Corporate Secretary

Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (“Ortho”), the world’s largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the closing of its sale of an additional 11.4 million ordinary shares

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $17.00 per share

Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share,

DENTSPLY SIRONA Inc., announced that the Company will host an investor conference call and live webcast on Monday, March 1, 2021 at 8:30 am ET and send out an earnings press release earlier that morning.

Neutra Corp. (OTC PINK: NTRR ) has decided to release a statement that management does not plan on having a share consolidation, also known as a reverse split at this time. Instead, the Company will focus on the growth of its wholly owned subsidiary VIVIS CBD.

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that CRN04894, the company’s lead adrenocorticotropic hormone (ACTH) antagonist for the treatment of diseases associated with excess ACTH such as Cushing’s disease and congenital adrenal hyperplasia (CAH)